| Summary: | Extensive drug resistance to bacterial infections in hospitalised patients is accompanied by high morbidity and mortality rates due to limited treatment options. This study investigated the clinical outcomes of single and combined antibiotic therapies in extensive (XDR), multidrug-resistant (MDR) and susceptible strains (SS) of hospital-acquired infections (HAIs). Cases of hospital-associated drug-resistant infections (HADRIs) and a few susceptible strains from hospital wards were selected for this study. Bacteria identifications (IDs) and antimicrobial susceptibility tests (ASTs) were performed with a Vitek 2 Compact Automated System. Patients’ treatment types and clinical outcomes were classified as alive improved (AI), alive not improved (ANI), or died. The length of hospital stay (LOHS) was acquired from hospital records. The HAI pathogens were <i>Acinetobacter baumannii</i> (28%), <i>Escherichia coli</i> (26%), <i>Klebsiella pneumoniae</i> (22%), <i>Klebsiella</i> (2%) species, <i>Pseudomonas aeruginosa</i> (12%), <i>Proteus mirabilis</i> (4%), and other <i>Enterobacteriaceae</i>. They were MDR (40.59%), XDR (24.75%), carbapenem-resistant <i>Enterobacteriaceae</i> (CRE, 21.78%) and susceptible (12%) strains. The treatments were either monotherapy or combined therapy with different outcomes. Monotherapy produced positive significant outcomes with <i>E. coli</i> infections, while for <i>P. aeruginosa,</i> there were no differences between the number of infections treated with either mono/combined therapies (50% each). Nonetheless, combined therapy had significant effects (<i>p</i> < 0.05) as a treatment for <i>A. baumannii</i> and <i>K. pneumoniae</i> infections. Clinical outcomes and LOHS varied with infecting bacteria. The prevalence of XDR and MDR HAIs was found to be significantly high, with no association with treatment type, LOHS, or outcome.
|
|---|